Sulphasalazine in ankylosing spondylitis: A prospective, randomized, double-blind, placebo-analysis of other controlled studies;Sulfasalazin bei spondylitis ankylosans: Eine prospektive, randomisierte, doppelblinde, placebo-kontrollierte studie und vergleich mit anderen kontrollierten studien

Zeitschrift fur Rheumatologie

Volumn 61, Issue 2, 2002, Pages 159-167

  Schmidt, W A ^a   Wierth, S ^a   Milleck, D ^a   Droste, U ^b   Gromnica Ihle, E ^a  

^a Rheumaklinik Berlin Buch   (Germany)

^b Karl Aschoff Klinik   (Germany)

Author keywords

Double blind method; Meta analysis; Spondylitis, ankylosing; Sulfasalazine

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIRHEUMATIC AGENTS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR; SPONDYLITIS, ANKYLOSING; SULFASALAZINE;

EID: 0036226095     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930200024     Document Type: Article

References (25)

1. Management of refractory ankylosing spondylitis and related spondylarthropathies
2. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: A department of veterans affairs cooperative study
3. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A department of veterans affairs cooperative study
4. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: Failure to demonstrate a clinical effect
5. Second-line treatment in seronegative spondylarthropathies
6. Methotrexate in severe ankylosing spondylitis: An open study
7. Sulphasalazine therapy in ankylosing spondylitis: Its effect on disease activity, immunoglobulin A, and the complex immunoglobulin A-alpha-1-antitrypsin
8. Sulphasalazine in ankylosing spondylitis: A double blind controlled study in 60 patients
9. Sulfasalazine in the treatment of spondylarthropathy: A randomized, multicenter, double-blind, placebo-controlled study
10. Sulphasalazine in ankylosing spondylitis
11. Meta-analysis of sulfasalazine in ankylosing spondylitis
12. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years
13. An open study of pamidronate in the treatment of refractory ankylosing spondylitis
14. Course of gut inflammation in spondylarthropathies and therapeutic consequences
15. Sulfasalazine in the treatment of ankylosing spondylitis: A twenty-six-week, placebo-controlled clinical trial
16. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicenter, double-blind, randomized, placebo-controlled study
17. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis
18. Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study
19. Sulphasalazine in ankylosing spondylitis: A radiological, clinical and laboratory assessment
20. Current guidelines for the drug treatment of ankylosing spondylitis
21. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria
22. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis
23. Treatment used by patients with ankylosing spondylitis. Comparison with the treatment preferences of rheumatologists
24. Treatment and prognosis of ankylosing spondylitis